Harrow, Inc. Payments of Debt Issuance Costs
Harrow, Inc. (HROW) reported Payments of Debt Issuance Costs of $555.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-10
- Harrow, Inc. payments of debt issuance costs for the quarter ending 2026-06-30 was $442.00K.
- Harrow, Inc. payments of debt issuance costs for the quarter ending 2026-03-31 was $113.00K.
- Harrow, Inc. payments of debt issuance costs for the quarter ending 2025-12-31 was $46.00K.
- Harrow, Inc. payments of debt issuance costs for the quarter ending 2025-09-30 was $1.58M.
- Harrow, Inc. payments of debt issuance costs for fiscal 2025 was $1.63M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $442.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $555.00K 10-Q · filed 2026-08-10 | $601.00K derived: sum of 3 quarters · filed 2026-08-10 | $2.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $113.00K 10-Q · filed 2026-05-11 | $159.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.74M derived: sum of 3 quarters · filed 2026-05-11 | |
| 2025-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.63M derived: sum of 2 quarters · filed 2026-03-02 | $1.63M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.58M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $100.00K 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |